Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Injection devices, diagnostic platforms, and interventional tools place Becton, Dickinson and Company (BD) at the heart of patient care—but they also generate sprawling disclosures that can exceed 300 pages. Finding where BD details FDA observations, segment margins, or litigation reserves is a challenge for busy professionals.
Stock Titan solves that problem. Our AI reads every line the moment it hits EDGAR, giving you Becton Dickinson SEC filings explained simply. Curious about a BD quarterly earnings report 10-Q filing? Get an instant summary of Life Sciences revenue shifts. Need Becton Dickinson insider trading Form 4 transactions? Real-time alerts flag each executive move. For deeper dives, open any document and let the platform highlight:
- Becton Dickinson annual report 10-K simplified—R&D spending, product safety notes, global supply-chain risks.
- Becton Dickinson 8-K material events explained—device recalls, acquisitions, leadership changes.
- Becton Dickinson proxy statement executive compensation—how incentives align with BD Medical, Life Sciences, and Interventional performance.
Whether you’re benchmarking margins with our BD earnings report filing analysis or monitoring Becton Dickinson executive stock transactions Form 4, the platform keeps you ahead. Spend less time decoding footnotes and more time acting on insights—understanding Becton Dickinson SEC documents with AI means clarity on every risk factor, growth driver, and insider trade in one place.
Becton, Dickinson and Company (BDX) has a class of debt securities, the 0.034% Notes due 2025, that the New York Stock Exchange has notified for removal from listing and registration by filing Form 25. The Exchange states it complied with rules governing delisting and the filing records that the issuer complied with the Exchange's requirements under 17 CFR 240.12d2-2(c) while the Exchange referenced compliance under 17 CFR 240.12d2-2(b).
Gregory Hayes, a director of Becton, Dickinson and Company (BDX), reported an insider purchase on 08/11/2025. The Form 4 shows an acquisition of 5,250 shares of BDX common stock at a price of $191.57, resulting in beneficial ownership of 6,046 shares held directly. The filing was executed by Donna Kalazdy by power of attorney for Mr. Hayes on 08/11/2025. The form was filed by one reporting person and lists Mr. Hayes address as c/o Becton, Dickinson and Company in Franklin Lakes, NJ.
Claire Fraser, a director of Becton, Dickinson and Company (BDX), reported a direct sale of common stock: 863 shares on 08/08/2025 at a reported price of $192.3 per share, leaving her with 23,143 shares beneficially owned directly. The Form 4 entry is coded as a sale and no derivative securities are reported in this filing.
Form 144 filed for Becton, Dickinson and Co. (BDX) indicates a proposed sale of 863 common shares, with an aggregate market value of $165,879.90, to be sold approximately on 08/08/2025 on the NYSE through Merrill Lynch. The filing shows 286,627,469 shares outstanding, so the proposed sale is a very small fraction of the company’s total shares. The securities were acquired on 01/24/2024 as a stock bonus from Claire Marie Fraser and were paid as compensation. The filer represents there are no undisclosed material adverse facts.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
